- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT04493814
Study Visceral Adipose Tissue and Liver Stifness in a Retrospective Cohort of Diabetes Mellitus Patients
Study of Association Between Quantity (and Percentage) of Visceral Adipose Tissue and NAFLD-linked Liver Stifness as Mesured by Fibroscan in a Retrospective Cohort of Diabetes Mellitus Patients
Non Alcoholic Fatty Liver Disease (NAFLD) is an emergent disease worldwide, and soon the leading cause of hepatic transplant in the USA. Among this high number of patients, the current challenge is to detect or even predict patients at risk of inflammation (Non Alcoholic or Steatohepatitis or NASH) and end-stage fibrosis, which are the best predictors of liver-related mortality.
Visceral obesity is intimately associated with metabolic disease and adverse health outcomes, such as diabetes, and NAFLD. It has been demonstrated that visceral adipose tissue-linked inflammation was a risk factor of stroke, myocardial infarction, and others metabolic-related complications.
The aim of this study was to evaluate the association of the quantity and percentage of Visceral Adipose Tissue by Dual X-Ray Absorptiometry and liver stiffness by Fibroscan in patients with type 2 diabetes, and other predictors of fibrosis such as FIB-4 and Fibrotest. We retrospectively collected the data of all the diabetic patients who had undergone a DEXA and a Fibroscan between January 1st, 2014 and Decembre 31th, 2019, in the Universitary Hospital of Nancy, France.
Studie Overzicht
Toestand
Conditie
Studietype
Inschrijving (Verwacht)
Contacten en locaties
Studie Locaties
-
-
-
Nancy, Frankrijk, 54500
- GUERCI Bruno
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Bemonsteringsmethode
Studie Bevolking
Beschrijving
Inclusion Criteria:
- Type 2 diabetes mellitus
- Patients who had undergone a VCTE examen at Universitary Hospital of Nancy between January 1st, 2014 and December 31th, 2019
- - Patients who had undergone a DEXA at Universitary Hospital of Nancy with less than one year of difference with VCTE
Exclusion Criteria:
- Viral, ethylic, drug-linked, genetic, self-immune hepatitis, liver cancer or metatasis ; other causes who could interact with fibroscan or biological markers (thrombocytopenia, undernutrition)
- Type 1 diabetes mellitus
- Weight variation (>5% of body weight) between DEXA mesure and Fibroscan mesure
- Fail of VCTE examination
- High alcohol consumption (>30g/day for men and >20g.day for women)
- Pregnant women
- Other causes of secondary hepatic steatosis (drug-linked, parenteral nutrition, rare diseases...)
- Any other pathology that the investigator would consider not compatible with the research
- Patients in any other research protocol three months before inclusion
- Person referred as in the Public Health code (articles L.1121-5, L.1121-7 and L.1121-8) : pregnant or nursing woman, minor adult, major adult under legal protection, adult unable of giving consent
- Person deprived of their liberty by judicial or administrative decision, person under psychiatric care as described in articles L. 3212-1 and L.3213-1.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
Cohorten en interventies
Groep / Cohort |
---|
Cohort
All the patients with type 2 diabetes followed at Universitary Hospital of Nancy who had undergone a DEXA and a Fibroscan between 2014 and 2019.
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
Association between quantity of Visceral adipose Tissu and Liver Stiffness
Tijdsspanne: July to September 2020
|
Visceral adipose tissu in grams mesured by DEXA, and Liver stiffness in kiloPascal mesured par Vibration-Controlled Transient Elastography
|
July to September 2020
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
Association between percentage of Visceral adipose Tissu and Liver Stiffness
Tijdsspanne: July to September 2020
|
Visceral adipose tissu in percentage on total fat mass mesured by DEXA, and Liver stiffness in kiloPascal mesured par Vibration-Controlled Transient Elastography
|
July to September 2020
|
Association between quantity of Visceral adipose Tissue and histologic Fibrosis
Tijdsspanne: July to September 2020
|
Visceral adipose tissu in grams mesured by DEXA, and histologic fibrosis determined on hepatic biopsy.
|
July to September 2020
|
Association between percentage of Visceral adipose Tissue and histologic Fibrosis
Tijdsspanne: July to September 2020
|
Visceral adipose tissu percentage on total fat mass mesured by DEXA, and histologic fibrosis determined on hepatic biopsy.
|
July to September 2020
|
Determine the diagnostic performances of quantity of Visceral adipose Tissue for histologic fibrosis diagnosis.
Tijdsspanne: July to September 2020
|
Visceral adipose tissu in grams mesured by DEXA, and histologic fibrosis determined on hepatic biopsy.
|
July to September 2020
|
Determine the diagnostic performances of percentage of Visceral adipose Tissue for histologic fibrosis diagnosis.
Tijdsspanne: July to September 2020
|
Visceral adipose tissu percentage on total fat mass mesured by DEXA, and histologic fibrosis determined on hepatic biopsy.
|
July to September 2020
|
Determine the diagnostic performances of different biologic markers for histologic fibrosis diagnosis.
Tijdsspanne: July to September 2020
|
Histologic fibrosis determined on hepatic biopsy.
|
July to September 2020
|
Build an algorithm with Visceral adipose Tissue mesured and biological markers to predict fibrosis.
Tijdsspanne: July to September 2020
|
Prediction algorithm for hepatic fibrosis based on different markers
|
July to September 2020
|
Medewerkers en onderzoekers
Sponsor
Studie record data
Bestudeer belangrijke data
Studie start (Verwacht)
Primaire voltooiing (Verwacht)
Studie voltooiing (Verwacht)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- 2019PI279
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .
Klinische onderzoeken op Type 2 diabetes
-
University of Trás-os-Montes and Alto DouroVoltooidDiabetes mellitus type 2 | Diabetesgerelateerde complicatiesPortugal
-
Diabetes Foundation, IndiaNational Diabetes Obesity and Cholesterol FoundationWervingDiabetes mellitus type 2 met complicatiesIndië
-
Wang SiqiChina-Japan Friendship HospitalNog niet aan het werven
-
HighTide Biopharma Pty LtdWervingDiabetes mellitus type 2China
-
Nanjing First Hospital, Nanjing Medical UniversityWervingDiabetes mellitus type 2China
-
CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.Nog niet aan het werven
-
Beijing Chao Yang HospitalNog niet aan het wervenDiabetes mellitus type 2China
-
Vinmec Research Institute of Stem Cell and Gene...VoltooidDiabetes mellitus type 2Vietnam
-
Eli Lilly and CompanyActief, niet wervendDiabetes mellitus type 2China, Verenigde Staten, Nederland, Spanje, Australië, Oostenrijk, Indië, Canada, Taiwan, Japan, Verenigd Koninkrijk, België, Frankrijk, Duitsland, Mexico, Roemenië, Italië, Argentinië, Brazilië, Puerto Rico, Oekraïne, Hongarije, Tsj... en meer
-
HighTide Biopharma Pty LtdShenzhen HighTide Biopharmaceutical Ltd.Voltooid